The United Kingdom and the United States have agreed to a major commercial pact that will keep zero import taxes on British pharmaceutical products being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase expenditure on pharmaceuticals through the NHS. This commitment ensures that tariffs on these key exports will be held at zero for a timeframe of the next three years.
This deal follows recent statements to significantly raise tariffs on branded drug imports, with increases mentioned up to one hundred percent.
"This arrangement with the United Kingdom reinforces the global environment for cutting-edge drugs and establishes much-needed equity to transatlantic pharmaceutical trade," an announcement said.
Economic Impact
Pharmaceuticals represent one of the Britain's most significant export categories to the America, which is clearly the biggest destination for leading companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to September, the UK exported medicines worth over eleven billion pounds to the US. This figure accounted for nearly one-fifth of all goods exports in that span.
"This deal safeguards employment, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a government official commented.
Detailed UK Commitments
The deal entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds were more than 20%.
Industry Background
The pact follows a ongoing row between the drug companies and the UK government over drug pricing and approval rates.
This friction were heightened by assertions that American customers were charged several times more for the identical medicines than consumers in the UK and Europe.
Recently, several significant drug company projects in the UK have been halted or abandoned, while major funding commitments have been announced toward projects in the United States.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the last ten years.
